These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 19915604)

  • 1. Current understanding of the pharmacogenomics of metformin.
    Zolk O
    Clin Pharmacol Ther; 2009 Dec; 86(6):595-8. PubMed ID: 19915604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatic drug transporters, old and new: pharmacogenomics, drug response, and clinical relevance.
    DeGorter MK; Kim RB
    Hepatology; 2009 Oct; 50(4):1014-6. PubMed ID: 19787812
    [No Abstract]   [Full Text] [Related]  

  • 3. Disposition of metformin: variability due to polymorphisms of organic cation transporters.
    Zolk O
    Ann Med; 2012 Mar; 44(2):119-29. PubMed ID: 21366511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin.
    Tzvetkov MV; Vormfelde SV; Balen D; Meineke I; Schmidt T; Sehrt D; Sabolić I; Koepsell H; Brockmöller J
    Clin Pharmacol Ther; 2009 Sep; 86(3):299-306. PubMed ID: 19536068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver.
    Nies AT; Koepsell H; Winter S; Burk O; Klein K; Kerb R; Zanger UM; Keppler D; Schwab M; Schaeffeler E
    Hepatology; 2009 Oct; 50(4):1227-40. PubMed ID: 19591196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanism of Altered Metformin Distribution in Nonalcoholic Steatohepatitis.
    Clarke JD; Dzierlenga AL; Nelson NR; Li H; Werts S; Goedken MJ; Cherrington NJ
    Diabetes; 2015 Sep; 64(9):3305-13. PubMed ID: 26016715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted disruption of organic cation transporter 3 attenuates the pharmacologic response to metformin.
    Chen EC; Liang X; Yee SW; Geier EG; Stocker SL; Chen L; Giacomini KM
    Mol Pharmacol; 2015 Jul; 88(1):75-83. PubMed ID: 25920679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics.
    Shu Y; Brown C; Castro RA; Shi RJ; Lin ET; Owen RP; Sheardown SA; Yue L; Burchard EG; Brett CM; Giacomini KM
    Clin Pharmacol Ther; 2008 Feb; 83(2):273-80. PubMed ID: 17609683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The MATE1 rs2289669 polymorphism affects the renal clearance of metformin following ranitidine treatment.
    Cho SK; Chung JY
    Int J Clin Pharmacol Ther; 2016 Apr; 54(4):253-62. PubMed ID: 26784938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influences of organic cation transporter polymorphisms on the population pharmacokinetics of metformin in healthy subjects.
    Yoon H; Cho HY; Yoo HD; Kim SM; Lee YB
    AAPS J; 2013 Apr; 15(2):571-80. PubMed ID: 23417334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. N(1)-methylnicotinamide as an endogenous probe for drug interactions by renal cation transporters: studies on the metformin-trimethoprim interaction.
    Müller F; Pontones CA; Renner B; Mieth M; Hoier E; Auge D; Maas R; Zolk O; Fromm MF
    Eur J Clin Pharmacol; 2015 Jan; 71(1):85-94. PubMed ID: 25552403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenetic variation and metformin response.
    Chen S; Zhou J; Xi M; Jia Y; Wong Y; Zhao J; Ding L; Zhang J; Wen A
    Curr Drug Metab; 2013 Dec; 14(10):1070-82. PubMed ID: 24329113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of novel promoter variants in MATE1 and MATE2 on the pharmacokinetics and pharmacodynamics of metformin.
    Stocker SL; Morrissey KM; Yee SW; Castro RA; Xu L; Dahlin A; Ramirez AH; Roden DM; Wilke RA; McCarty CA; Davis RL; Brett CM; Giacomini KM
    Clin Pharmacol Ther; 2013 Feb; 93(2):186-94. PubMed ID: 23267855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Organic cation transporter OCTs (SLC22) and MATEs (SLC47) in the human kidney.
    Motohashi H; Inui K
    AAPS J; 2013 Apr; 15(2):581-8. PubMed ID: 23435786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of SLC22A1 Polymorphisms on Metformin-Induced Reductions in Adiposity and Metformin Pharmacokinetics in Obese Children With Insulin Resistance.
    Sam WJ; Roza O; Hon YY; Alfaro RM; Calis KA; Reynolds JC; Yanovski JA
    J Clin Pharmacol; 2017 Feb; 57(2):219-229. PubMed ID: 27407018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic and Epigenetic Regulation of Organic Cation Transporters.
    Kölz C; Schaeffeler E; Schwab M; Nies AT
    Handb Exp Pharmacol; 2021; 266():81-100. PubMed ID: 33674913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rifampin enhances the glucose-lowering effect of metformin and increases OCT1 mRNA levels in healthy participants.
    Cho SK; Yoon JS; Lee MG; Lee DH; Lim LA; Park K; Park MS; Chung JY
    Clin Pharmacol Ther; 2011 Mar; 89(3):416-21. PubMed ID: 21270793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Variants in Pharmacokinetic Transporters and Glycemic Response to Metformin: A Metgen Meta-Analysis.
    Dujic T; Zhou K; Yee SW; van Leeuwen N; de Keyser CE; Javorský M; Goswami S; Zaharenko L; Hougaard Christensen MM; Out M; Tavendale R; Kubo M; Hedderson MM; van der Heijden AA; Klimčáková L; Pirags V; Kooy A; Brøsen K; Klovins J; Semiz S; Tkáč I; Stricker BH; Palmer C; 't Hart LM; Giacomini KM; Pearson ER
    Clin Pharmacol Ther; 2017 Jun; 101(6):763-772. PubMed ID: 27859023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interaction between polymorphisms in the OCT1 and MATE1 transporter and metformin response.
    Becker ML; Visser LE; van Schaik RH; Hofman A; Uitterlinden AG; Stricker BH
    Pharmacogenet Genomics; 2010 Jan; 20(1):38-44. PubMed ID: 19898263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renal tumours in a Tsc1+/- mouse model show epigenetic suppression of organic cation transporters Slc22a1, Slc22a2 and Slc22a3, and do not respond to metformin.
    Yang J; Kalogerou M; Gallacher J; Sampson JR; Shen MH
    Eur J Cancer; 2013 Apr; 49(6):1479-90. PubMed ID: 23228442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.